Contact Stephen

Speaking Engagements

  

In the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift.

16-17 November 2022
  

Current guidelines call for screening for only five types of cancer, and in each case for one type of cancer per screen. This means that there are no screening tests available for the majority of cancers, and far too often cancer is only detected once it has reached a later stage with much lower prognosis and more difficult to treat compared to whe

22-23 August 2023